PT  - JOURNAL ARTICLE
AU  - E. P. Kusnadi
AU  - A. S. Trigos
AU  - C. Cullinane
AU  - D. L. Goode
AU  - O. Larsson
AU  - J. R. Devlin
AU  - K. T. Chan
AU  - D. P. De Souza
AU  - M. J. McConville
AU  - G. A. McArthur
AU  - G. Thomas
AU  - E. Sanij
AU  - G. Poortinga
AU  - R. D. Hannan
AU  - K. M. Hannan
AU  - J. Kang
AU  - R. B. Pearson
TI  - Reprogrammed mRNA translation drives metabolic response to therapeutic targeting of ribosome biogenesis
AID  - 10.1101/847723
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 847723
4099  - http://biorxiv.org/content/early/2019/11/20/847723.short
4100  - http://biorxiv.org/content/early/2019/11/20/847723.full
AB  - Elevated ribosome biogenesis in oncogene-driven cancers is commonly targeted by DNA-damaging cytotoxic drugs. Our first-in-man trial of CX-5461, a novel, less genotoxic agent that specifically inhibits ribosome biogenesis via suppression of RNA Polymerase I transcription, revealed single agent efficacy in refractory blood cancers. Here we show that the marked improvement in the in vivo efficacy of CX-5461 in combination with PI3K/AKT/mTORC1 pathway inhibitors is associated with specific suppression of translation of mRNAs encoding regulators of cellular metabolism. Importantly, acquired resistance to this co-treatment is driven by translational re-wiring that results in dysregulated cellular metabolism and a cAMP-dependent pathway critical for the survival of blood cancers including lymphoma and acute myeloid leukemia. Our studies identify the molecular mechanisms responsible for the acute regulation of the translational apparatus and its functional adaptation upon selective drug-induced pressure, and will facilitate the rational design of more effective regimens for Pol I-directed ribosome targeting therapies.